Last week’s CT scan showed GG nodule had increased from 1.3 to 2.0 cm, another GG nodule was stable. Recurrence followed 4 months with Alimta maintenance every 4 weeks, followed mid February by a hiatus of 6 weeks before going on the 4 cycles of Carbo-Alimta.
Q: Could the hiatus of six weeks have contributed to the growth?
We may need to look at a 2nd line treatment. There is a phase III open label clinical trial where Roche's MPD3280A (ANTI PD-1L) is being compared with Docetaxel (NCT02008227) for patients with NSCLC after failure with platinum-containing chemo. Docetaxel is generally the preferred 2nd line of treatment. Immune therapy (PD-1L) is currently getting a lot of attention.
Question: Is this the best/most obvious clinical trial for mBAC patients who do not respond anymore to Carbo-Alimta and/or Alimta?
Would appreciate feedback from anyone familiar with this dilemma, how it was resolved, with what result, i.e., which other line of treatment like e.g., gemcitabine or navelbine.
My wife has BRAF V600E mutation. GSK's dabrafenib (Tafinlar) received Breakthrough Therapy designation for patients with metastatic BRAF V600E. Her cancer has not spread beyond her lungs.
Question: Anyone out there with mBAC - BRAF positive treated with dabrafenib?
My wife, 67 yrs.
DX Mar 11 NSCLC mBAC
Mar 11 lobectomy left LL & lower UL.
Scans: May 11 clean; July 11 bilateral GGOs; Sep 11 more prominent GGOs;
Feb 12 PET scan further growth, no mets, BRAF positive (V600E)
Mar 12 Carbo-Alimta chemo
Apr 12 CT improvement
Jun 12 CT continued improvement
Sep 12 CT stable
Jan 13 CT improvement
May 13 CT stable
Sep 13 CT stable, Alimta now once every 4 weeks
Jan 14 CT stable but new 1 cm GG nodule
Feb 14 CT GG nodule increased to 1.3 cm and a small on of few mms; if BAC was primary malignancy findings concerning for recurrence. Going on 4 cycles of Carboplatin-Alimta.
Mar 14 PET GG nodule has max SUV of 1.4.
May 14 CT GG nodule has grown to 2.0 cm